Daxor (DXR) Price & Analysis

Compare

93 Followers

DXR Stock Chart & Stats

$13.28

-$0.12(-1.54%)

At close: Jan 08 4:00 PM EST

$13.28

-$0.12(-1.54%)

Day’s Range― - ―

52-Week Range$6.55 - $14.00

Previous CloseN/A

Volume734.00

Average Volume (3M)4.92K

Market Cap

N/A

Enterprise Value$48.82M

Total Cash (Recent Filing)$0.00

Total Debt (Recent Filing)$262.93K

Price to Earnings (P/E)37.8

Beta0.53

Next Earnings

Feb 26, 2026

EPS EstimateN/A

Last Dividend Ex-Date

Jan 05, 2018

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.07

Shares Outstanding4,962,245

10 Day Avg. Volume2,756

30 Day Avg. Volume4,922

Financial Highlights & Ratios

PEG Ratio0.85

Price to Book (P/B)1.04

Price to Sales (P/S)17.48

P/FCF Ratio1.45K

Enterprise Value/Market Cap10.00T>

Enterprise Value/Revenue68.40

Enterprise Value/Gross Profit76.40

Enterprise Value/Ebitda22.14

Forecast

1Y Price Target

$22.00

Price Target Upside65.66% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Market ExpansionDaxor received 510(k) clearance from the FDA for its next-gen blood volume analyzer.

Product ApprovalDaxor's BVA diagnostic is the first FDA-approved system that provides direct blood volume measurements for patients.

Revenue GrowthDaxor's operating division delivered meaningful sales growth in the first half of the year, supported by increased utilization of single-use blood volume diagnostic kits, new account additions, and military contract revenue.

Bears Say

Dependency On Regulatory ApprovalsDaxor is investing in expanding its salesforce and production capabilities, which includes the acquisition of its supplier of radiopharmaceuticals.

Daxor News

Daxor to exhibit at the MedAxiom CV Transforum Fall’25 Conference

Daxor (DXR) Corporation announces it will be exhibiting at the MedAxiom Cardiovascular, CV, Transforum Fall’25 Conference being held...

13d ago

DXR

Daxor debuts FDA-cleared BVA analyzer at HFSA meeting

Daxor (DXR) Corporation announces significant commercial momentum and clinical validation following the Heart Failure Society of America Annual...

28d ago

DXR

Daxor unveils next-gen BVA analyzer at HFSA annual meeting

Daxor (DXR) Corporation will exhibit at the Heart Failure Society of America Annual Scientific Meeting in Minneapolis, Minnesota,...

1M ago

DXR

Daxor’s blood volume analysis validated for COVID, sepsis patients

Daxor (DXR) highlighted the significant findings of a new pilot study published in the Journal of Critical Care....

2M ago

DXR

Daxor reports increase in NAV to $7.15 per share

Daxor (DXR) Corporation provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and...

2M ago

DXR

Daxor’s FDA Clearance and Advancements Propel Buy Rating Amidst Growth Potential

Anthony Vendetti, an analyst from Maxim Group, reiterated the Buy rating on Daxor. The associated price target is...

3M ago

DXR

Why Is Daxor Stock (DXR) Up 20% Today?

Daxor stock rallied on Thursday after it received clearance from the FDA for its new Blood Volume Analyzer. ...

3M ago

DXR

Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories

Investors looking for all of the hottest stock market stories for Thursday are in the right place! ...

3M ago

AMD

Daxor Gains FDA Clearance for Blood Volume Analyzer

Daxor ( ($DXR) ) just unveiled an update. Daxor Corporation announced FDA 510(k) clearance for its next-generation Blood...

3M ago

DXR

Daxor receives FDA clearance for new BVA system

Daxor (DXR) Corporation announces FDA 510(k) clearance for its patent-pending next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer,...

3M ago

DXR

Daxor expands BVA technology into three new hospitals

Daxor (DXR) announces the expansion of its blood volume analysis technology into three new hospitals, a testament to...

3M ago

DXR

Daxor Approves Accounting Firm at Annual Meeting

Daxor ( ($DXR) ) has issued an update. Daxor Corporation held its Annual Meeting on June 24, 2025,...

4M ago

DXR

Daxor announces new findings from Duke University on BVA

Daxor (DXR) Corporation announces significant new findings from Duke University Medical Center published in the prestigious American Heart...

6M ago

DXR

Daxor announces expansion of diagnostic solutions into two healthcare systems

Daxor (DXR) announces the expansion of its diagnostic solutions into two additional U.S. healthcare systems, further advancing the...

6M ago

DXR

DXR FAQ

What was Daxor Corporation’s price range in the past 12 months?

Daxor Corporation lowest stock price was $6.55 and its highest was $14.00 in the past 12 months.

What is Daxor Corporation’s market cap?

Currently, no data Available

When is Daxor Corporation’s upcoming earnings report date?

Daxor Corporation’s upcoming earnings report date is Feb 26, 2026 which is in 121 days.

How were Daxor Corporation’s earnings last quarter?

Daxor Corporation released its earnings results on Aug 21, 2025. The company reported -$0.074 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.074.

Is Daxor Corporation overvalued?

According to Wall Street analysts Daxor Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Daxor Corporation pay dividends?

Daxor Corporation pays a Monthly dividend of $0.03 which represents an annual dividend yield of N/A. See more information on Daxor Corporation dividends here

What is Daxor Corporation’s EPS estimate?

Daxor Corporation’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Daxor Corporation have?

Daxor Corporation has 4,962,245 shares outstanding.

What happened to Daxor Corporation’s price movement after its last earnings report?

Daxor Corporation reported an EPS of -$0.074 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.498%.

Which hedge fund is a major shareholder of Daxor Corporation?

Currently, no hedge funds are holding shares in DXR

Company Description

Daxor Corporation

Daxor Corporation (DXR) is a medical instrumentation and biotechnology company that specializes in blood volume analysis technology. The company focuses on advancing healthcare by providing innovative diagnostic tools and services that enhance the understanding and treatment of various medical conditions. Daxor's flagship product, the BVA-100, is an FDA-cleared diagnostic device that measures human blood volume, aiding in the precise assessment of fluid management in patients.

Daxor (DXR) Earnings & Revenues

Historic Earnings Reports

DXR Stock 12 Month Forecast

Average Price Target

$22.00

▲(65.66% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","23":"$23","10.25":"$10.25","14.5":"$14.5","18.75":"$18.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,10.25,14.5,18.75,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2023","6":"Mar<br/>2024","9":"Mar<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.42,11.31076923076923,12.201538461538462,13.092307692307692,13.983076923076922,14.873846153846154,15.764615384615384,16.655384615384616,17.546153846153846,18.436923076923076,19.32769230769231,20.21846153846154,21.10923076923077,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.42,11.31076923076923,12.201538461538462,13.092307692307692,13.983076923076922,14.873846153846154,15.764615384615384,16.655384615384616,17.546153846153846,18.436923076923076,19.32769230769231,20.21846153846154,21.10923076923077,{"y":22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.42,11.31076923076923,12.201538461538462,13.092307692307692,13.983076923076922,14.873846153846154,15.764615384615384,16.655384615384616,17.546153846153846,18.436923076923076,19.32769230769231,20.21846153846154,21.10923076923077,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.79,"date":1630454400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.72,"date":1646092800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.7,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.3,"date":1682899200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.7,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.89,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.45,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.69,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.45,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.42,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >